01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market overview
03.2 Product offerings
04. Product Profiles
04.1.1 Celexa
04.1.2 Fetzima
04.1.3 Lexapro
04.1.4 Viibryd
04.1.5 Cymbalta
04.1.6 Prozac
04.1.7 Symbyax
04.1.8 Paxil
04.1.9 Wellbutrin
04.1.10 Abilify
04.1.11 Effexor
04.1.12 Pristiq
04.1.13 Zoloft
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disorder Overview
07.1 Types of depression
07.1.1 Major depressive disorder
07.1.2 Persistent depressive disorder
07.1.3 Psychotic depression
07.1.4 Postpartum depression
07.1.5 Seasonal affective disorder
07.1.6 Bipolar disorder
07.2 Etiology
07.3 Epidemiology
07.3.1 Bipolar disorder among adults
07.3.2 Dysthymic disorder among adults
07.3.3 Major depression among adults
07.3.4 Major depression among adolescents
07.4 Treatment and management
07.5 Economic burden
08. Market Landscape
08.1 Market overview
08.2 Market size and forecast
08.3 Depression drugs market in US 2014-2019
08.3.1 Market size and forecast
08.4 Five forces analysis
09. Market Segmentation by Mechanism of Action
10. Geographical Segmentation
10.1 Segmentation of global depression drugs market by geography 2014
11. Pipeline Portfolio
11.1 Key information on late-stage pipeline molecules
11.1.1 Brexpiprazole
11.1.2 ALKS 5461
11.1.3 Cariprazine
11.1.4 TGFK07AD
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive scenario
19.1.1 Key news
19.1.2 Mergers and acquisitions
19.2 Market share analysis 2014
19.2.1 Competitive assessment of top drugs used for treating depression
19.2.2 Bristol-Myers Squibb
19.2.3 Eli Lilly
19.2.4 Pfizer
19.2.5 GlaxoSmithKline
19.2.6 Actavis
19.3 Other and future prominent vendors
20. Key Vendor Analysis
20.1 Actavis
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Geographical segmentation by Sales 2013
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 Bristol-Myers Squibb
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Key Product Offerings
20.2.4 Revenue by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 Eli Lilly
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue
20.3.4 Sales by Geography
20.3.5 Business Strategy
20.3.6 Key Information
20.3.7 SWOT Analysis
20.4 GlaxoSmithKline
20.4.1 Key facts
20.4.2 Business overview
20.4.3 Business segmentation by revenue 2014
20.4.4 Business segmentation by revenue 2013 and 2014
20.4.5 Geographical segmentation by revenue 2014
20.4.6 Business strategy
20.4.7 Recent developments
20.4.8 SWOT analysis
20.5 Pfizer
20.5.1 Key facts
20.5.2 Business overview
20.5.3 Business segmentation by revenue 2014
20.5.4 Business segmentation by revenue 2013 and 2014
20.5.5 Geographical segmentation by revenue 2014
20.5.6 Business strategy
20.5.7 Key developments
20.5.8 SWOT analysis
21. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: NIMH classification of depression
Exhibit 3: Prevalence data for major depressive disorder among adults in US (2012)
Exhibit 4: Prevalence data for dysthymic disorder among adults in US (2012)
Exhibit 5: 12-month prevalence data for major depressive disorder with severe impairment among adults in US (2012)
Exhibit 6: Prevalence data for major depressive disorder among adults in US (2012)
Exhibit 7: Prevalence data for major depression among adults in US (2012)
Exhibit 8: WHO guidelines for management of depression
Exhibit 9: Economic burden of depression in US
Exhibit 10: Segmentation of costs associated with depression
Exhibit 11: Snapshot of economic burden of depression in US
Exhibit 12: Global depression drugs market 2014-2019 ($ millions)
Exhibit 13: Depression drugs market in US 2014-2019 ($ millions)
Exhibit 14: Segmentation of global depression drugs market by mechanism of action
Exhibit 15: Segmentation of global depression drugs market by mechanism of action 2014
Exhibit 16: Segmentation of global depression drugs market by geography 2014
Exhibit 17: Depression drugs: pipeline portfolio
Exhibit 18: Vendor ranking 2014
Exhibit 19: YoY growth rate of major depression drugs 2010-2014 ($ millions)
Exhibit 20: Revenue comparison of top drugs used for treating depression in 2013 ($ millions)
Exhibit 21: YoY global revenue of Abilify 2010-2014 ($ millions)
Exhibit 22: YoY global revenue of Cymbalta 2010-2014 ($ millions)
Exhibit 23: YoY global revenue of Pristiq 2010-2014 ($ millions)
Exhibit 24: YoY global revenue of Zoloft 2010-2014 ($ millions)
Exhibit 25: YoY global revenue of Effexor 2010-2014 ($ millions)
Exhibit 26: YoY global revenue of Wellbutrin 2010-2013 ($ millions)
Exhibit 27: YoY revenue of Wellbutrin in US 2010-2013 ($ millions)
Exhibit 28: YoY global revenue of Paxil 2010-2014 ($ millions)
Exhibit 29: Actavis: Business Segmentation
Exhibit 30: Actavis: Business Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 31: Actavis: Geographical segmentation by Sales 2013
Exhibit 32: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 33: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 34: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 35: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 36: Eli Lilly: Sales by Geography 2013
Exhibit 37: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 38: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 39: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 40: Pfizer: Business segmentation by revenue 2014
Exhibit 41: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 42: Pfizer: Geographical segmentation by revenue 2014